Cryo-Cell International Inc.
CCEL Healthcare Medical Care Facilities
Cryo-Cell International Inc.’s revenue for fiscal 2025 (year ended November 2025) was $31.6 million, down 1.31% from fiscal 2024. In the quarter to August 2026, revenue was flat, EPS grew 77.8%, free cash flow fell 58.4% and total debt fell 29.5%, each against the same quarter a year earlier.
Follow CCEL
Cryo-Cell International Inc. (CCEL) EV/Sales
As of 16 October 2026, Cryo-Cell International Inc. (CCEL) trades at a EV/Sales of 1.3×. Over the past ten years it has ranged from 0.8× (June 2015) to 4.0× (September 2021); the current reading is higher than 19% of that period. That is in line with the Medical Care Facilities industry median of 1.3× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.2× | (48.81%) |
| FY2024 | 2.4× | 42.99% |
| FY2023 | 1.7× | 11.83% |
| FY2022 | 1.5× | (53.88%) |
| FY2021 | 3.3× | 96.15% |
| FY2020 | 1.7× | (6.62%) |
| FY2019 | 1.8× | (8.63%) |
| FY2018 | 2.0× | (9.91%) |
| FY2017 | 2.2× | 32.47% |
| FY2016 | 1.7× | 27.16% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Aug 2026 | 1.3× | 11.84% |
| May 2026 | 1.1× | 6.14% |
| Feb 2026 | 1.1× | (14.60%) |
| Nov 2025 | 1.2× | (14.51%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DCGO DocGo Inc. compare | 0.0× |
| PAIYY Aesthetic Medical International Hldngs Group Ltd Sponsored ADR compare | 0.0× |
| PIII P3 Health Partners Inc. compare | 0.1× |
| PARK Park Dental Partners, Inc. compare | 0.3× |
| AIRS AirSculpt Technologies, Inc. compare | 0.8× |
| BTMD biote Corp. compare | 0.8× |
| CCEL Cryo-Cell International Inc. | 1.3× |
| JYNT The Joint Corp. compare | 1.4× |
| CCM Concord Medical Services Holdings Limited compare | 2.6× |
| Medical Care Facilities industry median | 1.3× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)